Login to Your Account

First antimembrane protein PROTAC

PROTACs successfully target receptor tyrosine kinases

By Anette Breindl
Senior Science Editor

Tuesday, November 28, 2017

Receptor tyrosine kinases (RTKs) are one of the biopharma industry's most familiar frenemies. Aberrant RTK signaling is a driver in many forms of cancer, and is targeted by dozens of inhibitors.

To continue reading subscribe now to Science News

Learn More about Science News

Already a subscriber? Sign In or Buy now to activate your subscription